SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-148827
Filing Date
2023-05-19
Accepted
2023-05-19 08:28:00
Documents
13
Period of Report
2023-05-19
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d511724d8k.htm   iXBRL 8-K 24953
2 EX-99.1 d511724dex991.htm EX-99.1 18912
  Complete submission text file 0001193125-23-148827.txt   174956

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tsha-20230519.xsd EX-101.SCH 2844
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20230519_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20230519_pre.xml EX-101.PRE 11703
7 EXTRACTED XBRL INSTANCE DOCUMENT d511724d8k_htm.xml XML 3468
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 23937959
SIC: 2836 Biological Products, (No Diagnostic Substances)